Form 4: Ionis Pharmaceuticals Director Joan E. Herman Receives Stock Options and Restricted Stock Units

Director Joan E. Herman received stock options and restricted stock units from Ionis Pharmaceuticals on July 1, 2024, as part of the company's non-employee director compensation policy.

Summary

• On July 1, 2024, Joan E. Herman, a director of Ionis Pharmaceuticals, received stock options and restricted stock units (RSUs) as part of the company's non-employee director compensation policy.
• The stock options grant was for 10,111 shares with an exercise price of $47.11 per share.
• These options vest 100% on either the first anniversary of the grant date (July 1, 2025) or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier, and expire on June 30, 2034.
• The RSU award was for 4,079 units, each representing a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• These RSUs also vest 100% on either the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier, and will be delivered on the July 15th following the vesting date.
• The grants were adjusted to ensure that the director's annual equity compensation does not exceed $450,000 based on the aggregate grant date fair value.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation for a company director, indicating a stable and well-governed company. The sentiment is neutral to positive.

Positives

• The equity grants align the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The director will receive shares of Ionis common stock or their equivalent cash value upon vesting of the restricted stock units.

Industry Context

Equity compensation is a common practice for directors of publicly traded companies to align their interests with shareholders and incentivize performance.

Comparison to Industry Standards

• Director compensation packages vary widely across the pharmaceutical industry depending on company size, performance, and board responsibilities.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and restricted stock units as part of their director compensation plans.
• The $450,000 limit on annual equity compensation appears to be within a reasonable range for a director of a company the size of Ionis Pharmaceuticals.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign that the director's interests are aligned with theirs.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Next Steps

• The director will hold the stock options and restricted stock units until they vest and are exercised or settled, respectively.

Key Dates